Le Lézard
Classified in: Health, Science and technology, Business
Subject: VEN

Tetherex Pharmaceuticals, Inc. Completes $50M Series B Financing

OKLAHOMA CITY, April 18, 2018 /PRNewswire/ -- Tetherex Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on developing novel selectin inhibitor products to treat thrombosis, inflammatory diseases and cancer, today announced that the company has successfully closed on a $50 million private placement of Series B preferred stock. Proceeds from the financing will be used to conduct a Phase 2 clinical trial evaluating the company's potential, first-in-class P-Selectin Glycoprotein Ligand-1 (PSGL-1) inhibitor candidate, SelK2, in the treatment of venous thromboembolism (VTE) in patients undergoing total knee replacement surgery. In addition, Tetherex intends to use funds from the offering to conduct a second Phase 2 trial evaluating SelK2 in Crohn's disease or other inflammatory indication.

The funding was led by MPM Capital and a group of Oklahoma-based investors including Dr. Philip Jones, a member of the Tetherex Board of Directors.

"Our research suggests that SelK2 can broadly impact venous thrombosis, inflammation, and cancer where selectin/receptor-mediated cell adhesion has been shown to play a key pathologic role," said Dr. Scott Rollins, chairman and chief executive officer of Tetherex. "The additional investment by MPM Capital, a leading life sciences investor, and the overall success of this latest financing speak to the strength of the scientific data supporting the potential of SelK2 as a new, potentially first-in-class therapeutic option for several indications. We look forward to advancing SelK2 into Phase 2 clinical development later this year."  

About SelK2
SelK2 is a humanized monoclonal antibody that binds PSGL-1 and blocks its interactions with both the selectin family of molecules and chemokines involved in exaggerated and destructive inflammatory responses in thromboembolic and inflammatory diseases.

About Tetherex Pharmaceuticals, Inc.
Tetherex Pharmaceuticals, Inc. is a privately held biopharmaceutical company focused on development of selectin inhibitor therapeutics for the treatment of a broad range of diseases including thrombosis, inflammation and cancer. More information is available at www.tetherex.com


Dr. Scott Rollins                         

Paula Schwartz

Chairman and CEO                     

Managing Director

Tetherex Pharmaceuticals, Inc.    

Rx Communications Group, LLC





SOURCE Tetherex Pharmaceuticals, Inc.

These press releases may also interest you

at 05:02
Cross-border finance has become a new growth point of ICBC (Asia) Cross-border finance is developing rapidly thanks to the opening up of China's capital market, opportunities brought by the development of the Guangdong-Hong Kong-Macao Greater Bay...

at 05:00
Zilliant, a company helping B2B enterprises turn data into actionable intelligence to accelerate profitable growth, today announced that customer Mestergruppen, a construction and building materials distributor based in Norway, has successfully...

at 05:00
JoVE is thrilled to announce an expanded partnership with the European Commission's Joint Research Centre (JRC), and the 3,000 researchers working at the JRC's six locations. As the publisher of the world's only peer-reviewed scientific video...

at 05:00
Digital marketing agency, fishbat, discusses how marketers can use social listening tools to improve their overall content marketing strategy. In today's digital age, quality content is king. To have an effective content marketing strategy,...

at 05:00
HSA Administrators, Clarity Benefit Solutions shares five ways broker can optimize their conversations for sales. With technology permeating all aspects of life, the art of conversation can get lost behind a screen. Brokers need to remember that...

at 05:00
Server Bays, a provider of  Managed IT services on Long Island, helps businesses beef up their security strategy with five tips. VoIP, or Voiceover Internet Protocol, has surpassed traditional communication services in functionality and...

News published on 18 april 2018 at 08:00 and distributed by: